The report on the Global Cystic Fibrosis Therapeutics Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of comprehensive research. The report gives a complete market analysis for the forecasted period from 2020 to 2026. The market is divided into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. The market size in terms of revenue (USD MN) is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.
Study period considered for research of global cystic fibrosis therapeutics market:
- Base Year: 2019
- Estimated Year: 2020
- Forecast Till: 2026
A glimpse of the major drivers and restraints affecting the cystic fibrosis therapeutics market is mentioned below:
Drivers
- Technological advancements in the R&D
- Increasing global awareness for cystic fibrosis therapy
- Increase in the prevalence of cystic fibrosis
Restraints
- High cost of treatment
- Increase in genetic mutation rate
The report offers a value chain analysis that gives a comprehensive outlook of the cystic fibrosis therapeutics market. The attractiveness analysis of this market has also been included so as to evaluate the segments that are anticipated to be profitable during the forecast period.
The cystic fibrosis therapeutics market has been segmented based on therapeutic products such as pulmozyme, TOBI, kalydeco, cayston, aeroquin, arikace and others. The study incorporates periodic market estimates and forecasts. Each therapeutic products has been analyzed based on the market size at regional and country levels.
The cystic fibrosis therapeutics market has been segmented based on molecule types such as biologics (enzymes) and small molecules (cystic fibrosis transmembrane conductance regulator (CFTR) modulator and antibiotics). The study incorporates periodic market estimates and forecasts. Each molecule type has been analyzed based on the market size at regional and country levels.
The cystic fibrosis therapeutics market has been segmented based on route of administration such as oral, parenteral, and topical. The report provides forecast and estimates for each route of administration in terms of market size during the study period. Each route of administration has been further analyzed based on regional and country levels.
The cystic fibrosis therapeutics market has been segmented based on dosage form such as solid, and liquid. The study incorporates periodic market estimates and forecasts. Each dosage form has been analyzed based on the market size at regional and country levels.
Geographically, the cystic fibrosis therapeutics market has been segmented into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The study details country-level aspects based on each segment and gives estimates in terms of market size.
The report also studies the competitive landscape of the global market with company profiles of players such as:
- Abbott Laboratories
- Actavis Generics
- Anthera Pharmaceuticals
- Arcturus Therapeutics
- Boehringer Ingelheim
- Chiesi Farmaceutici SpA
- F. Hoffmann-La Roche
- Genentech, Inc
- Genzyme Corp
- Gilead Sciences, Inc
- Insmed Inc
- Johnson & Johnson
- Merck Sharp & Dohme
- Neovii Biotech
- Novartis International AG
- Novo Nordisk
- PharmaSwiss S.A.
- Pharmaxis Ltd
- Proteostasis Therapeutics
- PTC Therapeutics
- United Medical
- Venus Remedies
- Vertex Pharmaceuticals
A detailed description of each has been included, with information in terms of headquarters, inception, stock listing, upcoming capacities, key mergers & acquisitions, financial overview, and recent developments. This analysis gives a thorough idea about the competitive positioning of market players. The report also gives information of cystic fibrosis therapeutics market’s mergers/acquisitions, partnerships, collaborations, new product launches, new product developments and other industry developments.
SEGMENTATIONS IN REPORT:
Cystic Fibrosis Therapeutics Market Analysis by Therapeutic Products:
- Pulmozyme
- TOBI
- Kalydeco
- Cayston
- Aeroquin
- Arikace
- Others
Cystic Fibrosis Therapeutics Market Analysis by Molecule Type:
- Biologics
- Small Molecules
- CFTR Modulator
- Antibiotics
Cystic Fibrosis Therapeutics Market Analysis by Route of Administration:
Cystic Fibrosis Therapeutics Market Analysis by Dosage Form:
Cystic Fibrosis Therapeutics Market Analysis by Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East And Africa
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.
The Global Cystic Fibrosis Therapeutics Market has been exhibited in detail in the following chapters -
Chapter 1 Cystic Fibrosis Therapeutics Market Preface
Chapter 2 Executive Summary
Chapter 3 Cystic Fibrosis Therapeutics Industry Analysis
Chapter 4 Cystic Fibrosis Therapeutics Market Value Chain Analysis
Chapter 5 Cystic Fibrosis Therapeutics Market Analysis By Sterilization Method
Chapter 6 Cystic Fibrosis Therapeutics Market Analysis By Type
Chapter 7 Cystic Fibrosis Therapeutics Market Analysis By Mode Of Delivery
Chapter 8 Cystic Fibrosis Therapeutics Market Analysis By End-User
Chapter 9 Cystic Fibrosis Therapeutics Market Analysis By Geography
Chapter 10 Competitive Landscape Of Cystic Fibrosis Therapeutics Companies
Chapter 11 Company Profiles Of Cystic Fibrosis Therapeutics Industry